Table Graph
      published meta-analysis   sensitivity analysis   studies

baricitinib in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] 0.54[0.31; 0.95]COV-BARRIER (critically ill), 202210%101NAnot evaluable deathsdetailed resultsCOV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] 0.54[0.31; 0.95]COV-BARRIER (critically ill), 202210%101NAnot evaluable clinical improvementdetailed resultsCOV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] 2.87[1.12; 7.36]COV-BARRIER (critically ill), 202210%101NAnot evaluable clinical improvement (14-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] 1.97[0.95; 4.09]COV-BARRIER (critically ill), 202210%101NAnot evaluable clinical improvement (28-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] 1.82[0.87; 3.81]COV-BARRIER (critically ill), 202210%101NAnot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] 1.57[0.77; 3.20]COV-BARRIER (critically ill), 202210%101NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-16 22:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 727 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons